Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenneth Akizuki

Orthopaedic Surgery San Francisco, CA Medical Doctor

NPI 1073569703 CMS profile 229490

2250 Hayes St Ste 208, San Francisco, CA 94117

Open in the dashboard

General payments

$24,650

70 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kenneth Akizuki of San Francisco, CA is reported in the CMS Open Payments database as having received $24,650 across 70 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $414 4
2024 General $76 2
2023 General $71 2
2022 General $5,156 16
2021 General $5,625 3
2020 General $41 2
2019 General $13,266 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Akizuki
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Kenneth Akizuki were reported at $414. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Kenneth Akizuki Orthopaedic Surgery median Middle half National median
2019 $13,266 $644 $140–$2,844 $163
2020 $41 $312 $75–$1,860 $114
2021 $5,625 $520 $117–$2,495 $132
2022 $5,156 $598 $128–$2,731 $149
2023 $71 $461 $128–$2,264 $160
2024 $76 $497 $134–$2,475 $164
2025 $414 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $11,553 41 payments
  2. Vericel Corporation $10,911 12 payments
  3. Smith+Nephew, Inc. $1,645 4 payments
  4. Evolution Surgical, Inc $238 5 payments
  5. NuVasive, Inc. $125 1 payment
  6. Merck Sharp & Dohme Corporation $65 2 payments
  7. Avanos Medical $51 2 payments
  8. Horizon Therapeutics plc $21 1 payment
  9. Kowa Pharmaceuticals America, Inc. $20 1 payment
  10. Bioventus LLC $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,000 2 payments
  2. Travel and Lodging $4,425 16 payments
  3. Honoraria $4,100 2 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $2,750 1 payment
  5. Consulting Fee $2,750 1 payment
  6. Food and Beverage $2,625 48 payments
Products named General payments · program years 2019–2025
  1. MACI Cellular Therapy $5,500 2 payments
  2. MACI Cellular Therapy $5,044 8 payments
  3. Latarjet System $760 3 payments
  4. MACI Orthopedics $367 2 payments
  5. XLIF $125 1 payment
  6. BRIDION $65 2 payments
  7. ON-Q* PUMP AND ACCESSORIES $51 2 payments
  8. PENNSAID $21 1 payment
  9. Seglentis $20 1 payment
  10. Exogen $20 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

229

Median for Orthopedic Surgery: 203

Drug cost

$1,644

Median for Orthopedic Surgery: $1,433

Branded share of claims

22.3%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 34 $504
Promethazine Hcl Generic 42 $248
Cephalexin Generic 41 $233
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 17 $232
Oxycodone Hcl Generic 23 $179
Ibuprofen Generic 49 $174
Prednisone Generic 23 $74

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$118,490

Of which drugs: $7,841

Medicare patients

276

Average age 73

Services billed

19,107

143 women, 133 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 49%
Ischemic heart disease 20%
Depression 15%
Cancer 14%
Osteoporosis 14%
Atrial fibrillation 13%
Chronic kidney disease 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg J7328 Office 19 16,632 $7,140
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 104 866 $637
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 105 758 $65

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

70 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record